[Meta] proposal — a flair for cagrilintide posts
proposal — a flair for cagrilintide posts, and it will stay as it is unless somebody makes the case to change it.
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
Amylin is co-secreted with insulin and acts on satiety and gastric emptying through its own receptor complexes. An amylin analogue is therefore not a variant of an incretin agonist — it is a different signalling axis.
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
If two or three other people have done the same thing we might actually learn something. Alone it is an anecdote.
best — the order this archive was captured in
Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
Independent result added to the log. Thank you for paying for it — there are very few on this compound.
Agreed — it is an amylin analogue and importing intuitions from the incretin boards produces confident nonsense.
this is a less-travelled board and the evidence base shows it
I would not extrapolate the tolerability profile from the monotherapy arm to the combination. The trials report them separately for a reason.
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.
Right, and the tolerability data in the combination arms is the part worth reading properly rather than summarising.
satiety signalling rather than incretin signalling
Right, and the tolerability data in the combination arms is the part worth reading properly rather than summarising.
Adding the standing caveat — nothing here is approved standalone and research material is not for human use.
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
What does the tolerability table in that paper actually say?
Yes. Anyone reading this board should hold their conclusions loosely until phase 3 reports.
Agreed that the monotherapy numbers look modest out of context and that the context is the whole story.
Cosigning on the thin independent data. Fewer members test this, so the bands are wider and should be treated that way.
the interesting data is the combination, not the monotherapy
amylin and GLP-1 are not redundant pathways
Careful — that is a dosing intuition carried over from another board and there is no basis for it here.
[deleted]
Are you comparing against a GLP-1 monotherapy result? They are not comparable.
Yes. The combination is where the interesting effect sizes are, and the monotherapy arms read very differently.
Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.
Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.
How many separate lots has anyone here tested?
Not convinced. Amylin signalling is not a GLP-1 pathway and the mechanism you are proposing conflates them.
Yes.
egfr_watcher is right that the evidence base here is thin. Conclusions should be held loosely.
read the combination arms separately from the monotherapy arms
- 1Yes. The combination is where the interesting effect sizes are, and the…7 comments in this branch · started by u/egfr_watcher